Safety and pharmacokinetics of repeat-dose micafungin in young infants

D. K. Benjamin, P. B. Smith, A. Arrieta, L. Castro, P. J. Sánchez, D. Kaufman, L. J. Arnold, L. L. Kovanda, T. Sawamoto, D. N. Buell, W. W. Hope, T. J. Walsh

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Given the risk of central nervous system infection, relatively high weight-based echinocandin dosages may be required for the successful treatment of invasive candidiasis and candidemia in young infants. This open-label study assessed the safety and pharmacokinetics (PK) of micafungin in 13 young infants (48h and 120 days of life) with suspected candidemia or invasive candidiasis. Infants of body weight 1,000 and 1,000g received 7 and 10mg/kg/day, respectively, for a minimum of 4-5 days. In the 7-mg/kg/day group, the mean baseline weight and gestational age were 2,101g and 30 weeks, respectively; in the 10-mg/kg/day group, they were 688g and 25 weeks, respectively. The median pharmacokinetic values for the 7-and 10-mg/kg/day groups, respectively, were as follows: area under the concentration-time curve from 0 to 24h (AUC 0-24), 258.1 and 291.2νgh/ml; clearance at steady state adjusted for body weight, 0.45 and 0.57ml/min/kg; maximum plasma concentration, 23.3 and 24.9ν g/ml; and volume of distribution at steady state adjusted for body weight, 341.4 and 542.8ml/kg. No deaths or discontinuations from treatment occurred. These data suggest that micafungin dosages of 7 and 10mg/kg/day are well tolerated and provide exposure levels that have been shown (in animal models) to be adequate for central nervous system coverage.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume87
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Invasive Candidiasis
Candidemia
Pharmacokinetics
Body Weight
Safety
Echinocandins
Weights and Measures
Central Nervous System Infections
Gestational Age
Area Under Curve
Central Nervous System
Animal Models
Therapeutics
micafungin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Benjamin, D. K., Smith, P. B., Arrieta, A., Castro, L., Sánchez, P. J., Kaufman, D., ... Walsh, T. J. (2010). Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clinical Pharmacology and Therapeutics, 87(1), 93-99. https://doi.org/10.1038/clpt.2009.200

Safety and pharmacokinetics of repeat-dose micafungin in young infants. / Benjamin, D. K.; Smith, P. B.; Arrieta, A.; Castro, L.; Sánchez, P. J.; Kaufman, D.; Arnold, L. J.; Kovanda, L. L.; Sawamoto, T.; Buell, D. N.; Hope, W. W.; Walsh, T. J.

In: Clinical Pharmacology and Therapeutics, Vol. 87, No. 1, 01.2010, p. 93-99.

Research output: Contribution to journalArticle

Benjamin, DK, Smith, PB, Arrieta, A, Castro, L, Sánchez, PJ, Kaufman, D, Arnold, LJ, Kovanda, LL, Sawamoto, T, Buell, DN, Hope, WW & Walsh, TJ 2010, 'Safety and pharmacokinetics of repeat-dose micafungin in young infants', Clinical Pharmacology and Therapeutics, vol. 87, no. 1, pp. 93-99. https://doi.org/10.1038/clpt.2009.200
Benjamin DK, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clinical Pharmacology and Therapeutics. 2010 Jan;87(1):93-99. https://doi.org/10.1038/clpt.2009.200
Benjamin, D. K. ; Smith, P. B. ; Arrieta, A. ; Castro, L. ; Sánchez, P. J. ; Kaufman, D. ; Arnold, L. J. ; Kovanda, L. L. ; Sawamoto, T. ; Buell, D. N. ; Hope, W. W. ; Walsh, T. J. / Safety and pharmacokinetics of repeat-dose micafungin in young infants. In: Clinical Pharmacology and Therapeutics. 2010 ; Vol. 87, No. 1. pp. 93-99.
@article{11d939a651824194ace67c9242c83cd6,
title = "Safety and pharmacokinetics of repeat-dose micafungin in young infants",
abstract = "Given the risk of central nervous system infection, relatively high weight-based echinocandin dosages may be required for the successful treatment of invasive candidiasis and candidemia in young infants. This open-label study assessed the safety and pharmacokinetics (PK) of micafungin in 13 young infants (48h and 120 days of life) with suspected candidemia or invasive candidiasis. Infants of body weight 1,000 and 1,000g received 7 and 10mg/kg/day, respectively, for a minimum of 4-5 days. In the 7-mg/kg/day group, the mean baseline weight and gestational age were 2,101g and 30 weeks, respectively; in the 10-mg/kg/day group, they were 688g and 25 weeks, respectively. The median pharmacokinetic values for the 7-and 10-mg/kg/day groups, respectively, were as follows: area under the concentration-time curve from 0 to 24h (AUC 0-24), 258.1 and 291.2νgh/ml; clearance at steady state adjusted for body weight, 0.45 and 0.57ml/min/kg; maximum plasma concentration, 23.3 and 24.9ν g/ml; and volume of distribution at steady state adjusted for body weight, 341.4 and 542.8ml/kg. No deaths or discontinuations from treatment occurred. These data suggest that micafungin dosages of 7 and 10mg/kg/day are well tolerated and provide exposure levels that have been shown (in animal models) to be adequate for central nervous system coverage.",
author = "Benjamin, {D. K.} and Smith, {P. B.} and A. Arrieta and L. Castro and S{\'a}nchez, {P. J.} and D. Kaufman and Arnold, {L. J.} and Kovanda, {L. L.} and T. Sawamoto and Buell, {D. N.} and Hope, {W. W.} and Walsh, {T. J.}",
year = "2010",
month = "1",
doi = "10.1038/clpt.2009.200",
language = "English (US)",
volume = "87",
pages = "93--99",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Safety and pharmacokinetics of repeat-dose micafungin in young infants

AU - Benjamin, D. K.

AU - Smith, P. B.

AU - Arrieta, A.

AU - Castro, L.

AU - Sánchez, P. J.

AU - Kaufman, D.

AU - Arnold, L. J.

AU - Kovanda, L. L.

AU - Sawamoto, T.

AU - Buell, D. N.

AU - Hope, W. W.

AU - Walsh, T. J.

PY - 2010/1

Y1 - 2010/1

N2 - Given the risk of central nervous system infection, relatively high weight-based echinocandin dosages may be required for the successful treatment of invasive candidiasis and candidemia in young infants. This open-label study assessed the safety and pharmacokinetics (PK) of micafungin in 13 young infants (48h and 120 days of life) with suspected candidemia or invasive candidiasis. Infants of body weight 1,000 and 1,000g received 7 and 10mg/kg/day, respectively, for a minimum of 4-5 days. In the 7-mg/kg/day group, the mean baseline weight and gestational age were 2,101g and 30 weeks, respectively; in the 10-mg/kg/day group, they were 688g and 25 weeks, respectively. The median pharmacokinetic values for the 7-and 10-mg/kg/day groups, respectively, were as follows: area under the concentration-time curve from 0 to 24h (AUC 0-24), 258.1 and 291.2νgh/ml; clearance at steady state adjusted for body weight, 0.45 and 0.57ml/min/kg; maximum plasma concentration, 23.3 and 24.9ν g/ml; and volume of distribution at steady state adjusted for body weight, 341.4 and 542.8ml/kg. No deaths or discontinuations from treatment occurred. These data suggest that micafungin dosages of 7 and 10mg/kg/day are well tolerated and provide exposure levels that have been shown (in animal models) to be adequate for central nervous system coverage.

AB - Given the risk of central nervous system infection, relatively high weight-based echinocandin dosages may be required for the successful treatment of invasive candidiasis and candidemia in young infants. This open-label study assessed the safety and pharmacokinetics (PK) of micafungin in 13 young infants (48h and 120 days of life) with suspected candidemia or invasive candidiasis. Infants of body weight 1,000 and 1,000g received 7 and 10mg/kg/day, respectively, for a minimum of 4-5 days. In the 7-mg/kg/day group, the mean baseline weight and gestational age were 2,101g and 30 weeks, respectively; in the 10-mg/kg/day group, they were 688g and 25 weeks, respectively. The median pharmacokinetic values for the 7-and 10-mg/kg/day groups, respectively, were as follows: area under the concentration-time curve from 0 to 24h (AUC 0-24), 258.1 and 291.2νgh/ml; clearance at steady state adjusted for body weight, 0.45 and 0.57ml/min/kg; maximum plasma concentration, 23.3 and 24.9ν g/ml; and volume of distribution at steady state adjusted for body weight, 341.4 and 542.8ml/kg. No deaths or discontinuations from treatment occurred. These data suggest that micafungin dosages of 7 and 10mg/kg/day are well tolerated and provide exposure levels that have been shown (in animal models) to be adequate for central nervous system coverage.

UR - http://www.scopus.com/inward/record.url?scp=72849119258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849119258&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.200

DO - 10.1038/clpt.2009.200

M3 - Article

C2 - 19890251

AN - SCOPUS:72849119258

VL - 87

SP - 93

EP - 99

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -